Amgen Reports Second Quarter 2016 Financial Results

THOUSAND OAKS, Calif., July 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include: Revenues increased 6 percent versus the second quarter of 2015 to $5.7 billion. Product sales grew 5 percent driven by Enbrel® (etanercept), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab). GAAP earnings per share (EPS) increased 15 percent to $2.47 driven by higher revenues and higher operating margins. GAAP operating income increased 15 percent to $2,380 million and GAAP operating margin improved by 3.8 percentage points to 43.5 percent. Non-GAAP EPS increased 11 percent t...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news